Pfizer, looking for a jumpstart, leans into cancer drug research

Pfizer believes the answer to its sliding valuation lies in oncology. The company, which is coming off one of the worst years in its history, unveiled on Thursday a new business unit dedicated to cancer research. The division, created in the wake of Pfizer’s $43 billion buyout of Seagen last year,…#pfizer #seagen #leerinkpartners #davidrisinger #ibrance #elilillys #novartis #adcetris #padcev #phase3
Source: Reuters: Health - Category: Consumer Health News Source Type: news